{
    "data": [
        {
            "id": "4032799",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-27T04:52:07-05:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Is Poised To Break Out In 2017",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4032799-bristol-myers-is-poised-to-break-out-in-2017"
            }
        },
        {
            "id": "4031138",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-17T15:14:24-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Just Isn't Sexy Anymore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4031138-bristol-myers-just-isnt-sexy-anymore"
            }
        },
        {
            "id": "4024919",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-20T01:32:10-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Meyers Squibb: Dividend Depends On New Product Becoming Even More Successful",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4024919-bristol-meyers-squibb-dividend-depends-on-new-product-becoming-even-successful"
            }
        },
        {
            "id": "4023267",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-14T15:37:00-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Roche And Bristol Face Bladder Cancer Threats",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4023267-roche-and-bristol-face-bladder-cancer-threats"
            }
        },
        {
            "id": "4023135",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-14T11:02:56-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol's Bid To Get Ahead In Head And Neck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4023135-bristols-bid-to-get-ahead-in-head-and-neck"
            }
        },
        {
            "id": "4019684",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-04T13:06:29-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Good Operating Leverage, Encouraging EPS Forecast",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41541",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180264",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4019684-bristol-myers-squibb-good-operating-leverage-encouraging-eps-forecast"
            }
        },
        {
            "id": "4015569",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-27T06:12:44-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Expect No Breakthrough In Bristol-Myers Squibb's Coming Dividend Hike",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4015569-expect-no-breakthrough-in-bristol-myers-squibbs-coming-dividend-hike"
            }
        },
        {
            "id": "4012842",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-18T12:02:35-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I'm Still Bullish On Bristol-Myers Despite Latest Release",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4012842-why-still-bullish-on-bristol-myers-despite-latest-release"
            }
        },
        {
            "id": "4012439",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-17T05:26:28-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I've Been Buying Bristol-Myers Into Weakness",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4012439-why-buying-bristol-myers-weakness"
            }
        },
        {
            "id": "4012217",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-14T14:41:08-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Waits For The Other PD-1 Shoe To Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4012217-bristol-waits-for-pdminus-1-shoe-to-drop"
            }
        },
        {
            "id": "4012182",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-14T12:48:46-04:00",
                "isLockedPro": false,
                "commentCount": 206,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotech Forum Daily Digest: The Donald Tanks Biotech. Spotlight On Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4012182-biotech-forum-daily-digest-donald-tanks-biotech-spotlight-on-bristol-myers-squibb"
            }
        },
        {
            "id": "4011902",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-13T09:52:15-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Tesaro Tops The Risers While Bristol-Myers Battered\ufeff\ufeff\ufeff\ufeff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011902-tesaro-tops-risers-while-bristol-myers-battered"
            }
        },
        {
            "id": "4011488",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-11T13:14:37-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Vs. Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011488-bristol-myers-squibb-vs-johnson-and-johnson"
            }
        },
        {
            "id": "4011464",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-11T12:06:15-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: The Opdivo Fiasco",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179331",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4011464-bristol-myers-squibb-opdivo-fiasco"
            }
        },
        {
            "id": "4011466",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-11T11:34:43-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Opdivo Plays Catch-Up In Head And Neck Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011466-opdivo-plays-catch-up-in-head-and-neck-cancer"
            }
        },
        {
            "id": "4006937",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-19T02:04:33-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Finally, Time To Buy Bristol-Myers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4006937-finally-time-to-buy-bristol-myers"
            }
        },
        {
            "id": "4005871",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-13T10:02:34-04:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Has Reached Bottom",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4005871-bristol-myers-squibb-reached-bottom"
            }
        },
        {
            "id": "4003909",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-02T19:16:40-04:00",
                "isLockedPro": false,
                "commentCount": 168,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Forward! Progressively Less For Biotech To Fear From Hillary",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177941",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4003909-forward-progressively-less-for-biotech-to-fear-from-hillary"
            }
        },
        {
            "id": "4002427",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-26T14:13:52-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Merck Versus Bristol Showdown",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4002427-merck-versus-bristol-showdown"
            }
        },
        {
            "id": "4000776",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-19T01:34:48-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Profit From Bristol-Myers' Drug Failure And Increased Volatility",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4000776-profit-from-bristol-myers-drug-failure-and-increased-volatility"
            }
        },
        {
            "id": "3999228",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-12T14:34:30-04:00",
                "isLockedPro": false,
                "commentCount": 98,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers: Science Trumps The Headlines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177094",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3999228-bristol-myers-science-trumps-headlines"
            }
        },
        {
            "id": "3998462",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-10T15:53:36-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol's Opdivo Fall-Out Brings Others Into Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3998462-bristols-opdivo-fall-out-brings-others-play"
            }
        },
        {
            "id": "3998294",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-10T11:28:47-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Bristol-Myers Squibb Drug Bust",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102095",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "176988",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3998294-bristol-myers-squibb-drug-bust"
            }
        },
        {
            "id": "3997927",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-09T16:41:00-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I'm Buying Bristol-Myers Squibb On The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3997927-buying-bristol-myers-squibb-on-dip"
            }
        },
        {
            "id": "3997299",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-08T12:33:55-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Swings For The Fences And Strikes Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3997299-bristol-swings-for-fences-and-strikes-out"
            }
        },
        {
            "id": "3997287",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-08T12:04:03-04:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Buy On The Drop?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74295",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "176896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3997287-bristol-myers-squibb-buy-on-drop"
            }
        },
        {
            "id": "3997254",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-08T11:10:59-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Opdivo's Recent Clinical Failure And The Implications For Gilead Science",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3997254-opdivos-recent-clinical-failure-and-implications-for-gilead-science"
            }
        },
        {
            "id": "3996856",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-07T02:13:57-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Buy It Even Cheaper",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21652",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3996856-bristol-myers-squibb-buy-even-cheaper"
            }
        },
        {
            "id": "3996579",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-05T16:40:04-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Opdivo Development May Have Finally Reached A Roadblock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "176838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3996579-opdivo-development-may-finally-reached-roadblock"
            }
        },
        {
            "id": "3996536",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-05T15:59:18-04:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Bristol-Myers' Fall Justified?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3996536-is-bristol-myers-fall-justified"
            }
        },
        {
            "id": "3996515",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-05T14:51:08-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Opdivo Misses In NSCLC: Implications For Bristol-Myers Squibb, Merck And Others",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "176834",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3996515-opdivo-misses-in-nsclc-implications-for-bristol-myers-squibb-merck-and-others"
            }
        },
        {
            "id": "3989565",
            "type": "article",
            "attributes": {
                "publishOn": "2016-07-19T15:44:59-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Top Of Its Game: Bristol-Myers Squibb's Opdivo Is Poised To Break On Through In Head And Neck Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3989565-top-of-game-bristol-myers-squibbs-opdivo-is-poised-to-break-on-through-in-head-and-neck"
            }
        },
        {
            "id": "3987663",
            "type": "article",
            "attributes": {
                "publishOn": "2016-07-11T17:05:05-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Deal, Juno Collapse Underscore Immuno-Oncology Risk/Reward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101972",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3987663-bristol-deal-juno-collapse-underscore-immuno-oncology-risk-reward"
            }
        },
        {
            "id": "3986913",
            "type": "article",
            "attributes": {
                "publishOn": "2016-07-07T11:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Buys Back Medarex Discard",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3986913-bristol-myers-buys-back-medarex-discard"
            }
        },
        {
            "id": "3984804",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-28T06:03:20-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Opdivo Is A Breakthrough For BMY In Bladder Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "175222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3984804-opdivo-is-breakthrough-for-bmy-in-bladder-cancer"
            }
        },
        {
            "id": "3982824",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-18T10:54:23-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Bristol-Myers Continue To Post Double-Digit Earnings Beats?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "73075",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "174814",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3982824-can-bristol-myers-continue-to-post-double-digit-earnings-beats"
            }
        },
        {
            "id": "3982244",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-15T13:30:10-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "BMY On The CheckMate Tear: Updated Results In Hodgkin Lympoma For Opdivo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "174697",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3982244-bmy-on-checkmate-tear-updated-results-in-hodgkin-lympoma-for-opdivo"
            }
        },
        {
            "id": "3982129",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-15T06:37:52-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Takeover Premium May Be Building",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "99676",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3982129-bristol-myers-squibbs-takeover-premium-may-be-building"
            }
        },
        {
            "id": "3981277",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-10T11:38:22-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Therapy Focus - First-Line Lung Cancer Is An Opdivo Vs. Keytruda Showdown",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3981277-therapy-focus-first-line-lung-cancer-is-opdivo-vs-keytruda-showdown"
            }
        },
        {
            "id": "3979766",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-03T15:25:02-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Bristol-Myers Squibb Checkmate Colorectal Cancer Now?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "174220",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3979766-will-bristol-myers-squibb-checkmate-colorectal-cancer-now"
            }
        },
        {
            "id": "3979077",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-01T08:39:10-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Expect Future Multi-Modality, Immune-Based Approaches To Solid Cancers To Include A Neoantigen Vaccine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3979077-expect-future-multi-modality-immune-based-approaches-to-solid-cancers-to-include-neoantigen"
            }
        },
        {
            "id": "3976069",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-18T14:31:35-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "New Approval Cements Bristol-Myers Squibb's Dominance Of Immunotherapy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "173510",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3976069-new-approval-cements-bristol-myers-squibbs-dominance-of-immunotherapy"
            }
        },
        {
            "id": "3974501",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-12T12:05:45-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Bristol-Myers Squibb's Immunotherapy Leadership Means For Your Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "173246",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3974501-what-bristol-myers-squibbs-immunotherapy-leadership-means-for-your-portfolio"
            }
        },
        {
            "id": "3968959",
            "type": "article",
            "attributes": {
                "publishOn": "2016-04-28T10:37:04-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Earnings Overview",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "172592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3968959-bristol-myers-squibb-earnings-overview"
            }
        },
        {
            "id": "3962818",
            "type": "article",
            "attributes": {
                "publishOn": "2016-04-03T22:09:40-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is Crushing Its Competition In The Cancer Treatment Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3962818-bristol-myers-squibb-is-crushing-competition-in-cancer-treatment-market"
            }
        },
        {
            "id": "3959895",
            "type": "article",
            "attributes": {
                "publishOn": "2016-03-21T09:34:15-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Immune Checkpoint Update: How Brisol-Myers Squibb Is Leading The Pack In (Formerly) Deadly Forms Of Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3959895-immune-checkpoint-update-how-brisol-myers-squibb-is-leading-pack-in-formerly-deadly-forms-of"
            }
        }
    ]
}